QuatRx CEO will present an update on QuatRx clinical development programs including review of positive results from the Phase 3 pivotal trial for
ANN ARBOR, Mich., Jan. 4 /PRNewswire/ -- QuatRx Pharmaceuticals Company today announced that the company chief executive officer, Robert L. Zerbe, M.D., will be a presenter at the 26th Annual JP Morgan Healthcare Conference on Tuesday, January 8th, 2008, at 9:30 a.m., Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco from January 7 to 10, 2008.
Dr. Zerbe will present an update on clinical development programs at QuatRx including a review of the positive results from a pivotal phase 3 trial for Ophena(TM) (ospemifene) for the treatment of postmenopausal vaginal syndrome (PVS). Results of the pivotal phase 3 trial for Ophena(TM) were announced by QuatRx on January 3, 2008.
QuatRx Pharmaceuticals is focused on the discovery, licensing,
development and commercialization of compounds in the endocrine, metabolic
and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has
three other product candidates in active clinical development and two
preclinical development programs. Fispemifene is a new selective estrogen
receptor antagonist that is in Phase 2 studies as an oral treatment for the
symptoms of secondary hypogonadism in men. QRX-431, a novel, selective
thyroid receptor beta agonist, is in Phase 1 studies as a potential
treatment for lipid disorders and obesity. Asord(TM) (becocalcidiol), a
novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment
of psoriasis through QuatRx's partner, CollaGenex Pharmaceuticals, Inc.
QuatRx's two preclinical small molecule programs are designed to address
common endocrine disorders in women and men. In Europe, QuatRx operates
through its Finnish subsidiary, Hormos Medical Ltd, located in Turku,
Finland. For press releases
|SOURCE QuatRx Pharmaceuticals Company|
Copyright©2008 PR Newswire.
All rights reserved